LY3314814: Phase II/III ongoing

AstraZeneca and Eli Lilly said an IDMC recommended continuation of the double-blind, placebo-controlled, international Phase II/III AMARANTH trial

Read the full 180 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE